ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis.
Ben Yi TewAlex J KalfaZeyi YangKyle M HurthThomas SimonEric AbnoosianStephen T DurantPetra HamerlikBodour SalhiaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our results demonstrate that AZD1390 effectively sensitizes breast cancer CNS metastasis to radiation therapy in DDR mutant tumors. This study demonstrates the potential of using AZD1390 as a novel therapeutic agent for patients with breast cancer CNS metastasis.